Rabbit Recombinant Monoclonal Pirh2 antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: PBS
WB | IHC-P | ICC/IF | |
---|---|---|---|
Human | Tested | Expected | Expected |
Mouse | Predicted | Expected | Expected |
Rat | Predicted | Expected | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes For antigen retrieval, heat up to 98 degree C, below boiling, and then let cool for 10-20 minutes. Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species Rat | Dilution info - | Notes For antigen retrieval, heat up to 98 degree C, below boiling, and then let cool for 10-20 minutes. Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species Human | Dilution info - | Notes For antigen retrieval, heat up to 98 degree C, below boiling, and then let cool for 10-20 minutes. Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info Use at an assay dependent concentration. | Notes - |
E3 ubiquitin-protein ligase that mediates ubiquitination of target proteins, including p53/TP53, TP73, HDAC1 and CDKN1B (PubMed:16914734, PubMed:17721809, PubMed:18006823, PubMed:19043414, PubMed:19483087, PubMed:21994467). Mediates ubiquitination and degradation of p53/TP53; preferentially acts on tetrameric p53/TP53 (PubMed:19043414, PubMed:19483087). Catalyzes monoubiquitinates the translesion DNA polymerase POLH (PubMed:21791603). Involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: RCHY1 acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation (PubMed:33909987). Isoform 4. Has no E3 ubiquitin-protein ligase activity.
ARNIP, CHIMP, PIRH2, RNF199, ZNF363, RCHY1, RING finger and CHY zinc finger domain-containing protein 1, Androgen receptor N-terminal-interacting protein, CH-rich-interacting match with PLAG1, E3 ubiquitin-protein ligase Pirh2, RING finger protein 199, RING-type E3 ubiquitin transferase RCHY1, Zinc finger protein 363, p53-induced RING-H2 protein, hPirh2
Rabbit Recombinant Monoclonal Pirh2 antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: PBS
ab250981 is the carrier-free version of Anti-Pirh2 antibody [EPR14980] ab189247.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Pirh2 also known as RCHY1 is a protein with E3 ubiquitin ligase activity. It has a molecular mass of approximately 34 kDa. Pirh2 targets proteins for degradation by the ubiquitin-proteasome system regulating the levels of proteins like p53. Expression of Pirh2 occurs in various tissues including liver and heart. It helps maintain cellular protein homeostasis by marking specific substrates for degradation.
Pirh2 influences the regulation of protein stability by tagging proteins for degradation. Besides p53 it acts on other substrates and engages in various cellular processes. Pirh2 operates independently and its presence affects cellular responses to stress and DNA damage. It modulates cell cycle progression and apoptosis impacting cell fate decisions.
Pirh2 plays an important role in the p53 signaling pathway an essential cell regulatory network. By mediating the ubiquitination of p53 Pirh2 affects cell survival and division under stress conditions. Interaction with proteins such as Mdm2 further regulates p53 activity impacting the cell's ability to respond to DNA damage and carcinogen exposure.
Research connects Pirh2 with the development of cancers. Its interaction with the tumor suppressor protein p53 poses effects on tumorigenesis by altering p53 stability and function. Overexpression of Pirh2 has connections to several cancer types including breast and liver cancers. These associations suggest Pirh2 as a potential target for therapeutic interventions that aim at modulating the p53 pathway to treat cancer.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using the same antibody clone in a different buffer formulation (Anti-Pirh2 antibody [EPR14980] ab189247).
Lanes 1-4: Merged signal (red and green). Green - Anti-Pirh2 antibody [EPR14980] ab189247 observed at 30 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Pirh2 antibody [EPR14980] ab189247 Recombinant Anti-Pirh2 antibody [EPR14980] was shown to specifically react with RCHY1 in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human RCHY1 (Pirh2) knockout HeLa cell line ab265478 (knockout cell lysate Human RCHY1 (Pirh2) knockout HeLa cell lysate ab258171) was used. Wild-type and RCHY1 knockout samples were subjected to SDS-PAGE. Anti-Pirh2 antibody [EPR14980] ab189247 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Pirh2 antibody [EPR14980] (Anti-Pirh2 antibody [EPR14980] ab189247) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: RCHY1 knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human RCHY1 (Pirh2) knockout HeLa cell line (Human RCHY1 (Pirh2) knockout HeLa cell line ab265478)
Lane 3: HepG2 cell lysate at 20 µg
Lane 4: Daudi cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 30 kDa
Observed band size: 30 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com